An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir

Intern Med. 2020 Jan 15;59(2):285-287. doi: 10.2169/internalmedicine.3498-19. Epub 2019 Sep 18.

Abstract

Patients with HIV infection represent a high-risk group for medication overdose because of the high frequency of complicating psychiatric disorders. Raltegravir is well-known for its low frequency of adverse effects. We herein report a 42-year-old Japanese man with HIV infection who was hospitalized 6 hours after overdosing with 24,000 mg of raltegravir in a suicide attempt. No serious adverse events occurred, although the plasma concentration of raltegravir at 18 hours after the overdose was 79,871.1 ng/mL. Raltegravir may be well-indicated for HIV patients at risk of overdosing.

Keywords: adverse event; attempting suicide; overdosing; pharmacokinetics; raltegravir.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-HIV Agents / administration & dosage*
  • Anti-HIV Agents / therapeutic use
  • Drug Overdose / pathology*
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Raltegravir Potassium / administration & dosage*
  • Raltegravir Potassium / therapeutic use

Substances

  • Anti-HIV Agents
  • Raltegravir Potassium